Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

ProMIS Neurosciences Inc. - Common Shares (NQ:PMN)

14.66 -0.20 (-1.35%)

Streaming Delayed Price Updated: 4:00 PM EDT, Aug 17, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	25,087
Open	14.69
Bid (Size)	14.40 (200)
Ask (Size)	14.72 (100)
Prev. Close	14.86
Today's Range	14.27 - 14.96
52wk Range	6.270 - 27.40
Shares Outstanding	32,689,190
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Promis Neurosciences Q2 Earnings Call Highlights ↗

August 13, 2026

Promis Neurosciences (NASDAQ:PMN) reported second-quarter 2026 results and highlighted blinded six-month interim data from its Phase 1b PRECISE-AD study of PMN310, an investigational antibody for early...

Via MarketBeat

ProMIS Neurosciences Reports Q2 2026 Results: Full Earnings Call Transcript ↗

August 13, 2026

On Thursday, ProMIS Neurosciences (NASDAQ:PMN) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For...

Via Benzinga

Performance

YTD	+105.5%	+105.5%
1 Month	-3.5%	-3.5%
3 Month	+40.5%	+40.5%
6 Month	-9.3%	-9.3%
1 Year	-5.0%	-5.0%

More News

ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights

August 13, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Report Second Quarter 2026 Financial Results and Business Update on August 13, 2026

August 03, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Promis Reports No ARIA-E in PMN310 Alzheimer’s Trial Interim Data ↗

July 28, 2026

Via MarketBeat

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease Trial

July 28, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 27, 2026

Via Benzinga

ProMIS Neurosciences to Host Webinar to Discuss Upcoming 6-Month Blinded Interim Data from PRECISE-AD Phase 1b Trial of PMN310 in Alzheimer’s Disease

July 27, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026

July 14, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Participate in Upcoming Conferences in June

May 28, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces First Quarter 2026 Financial Results and Provides Corporate Highlights

May 12, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces Full Year 2025 Financial Results and Provides Corporate Highlights

March 25, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™)

March 18, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

February 04, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

There are notable gap-ups and gap-downs in today's session. ↗

January 30, 2026

Via Chartmill

Which stocks are moving before the opening bell on Friday? ↗

January 30, 2026

Via Chartmill

ProMIS Neurosciences Announces Up to $175 Million Private Placement Financing

January 30, 2026

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Exceeds Target Enrollment in PRECISE-AD Phase 1b Clinical Trial of PMN310 in Alzheimer’s Disease

December 18, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

December 10, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences Announces New Peer-Reviewed Publication Showing Plasma pTau as a Predictive Early Endpoint in Alzheimer’s trials, Supporting its Ongoing Phase 1b PRECISE-AD trial with PMN310

December 01, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

ProMIS Neurosciences to Participate in the 8th Annual Evercore Healthcare Conference

December 01, 2025

From ProMIS Neurosciences Inc.

Via GlobeNewswire

Which stocks are experiencing notable movement on Monday? ↗

November 24, 2025

Via Chartmill

Top movers in Monday's session ↗

November 24, 2025

Via Chartmill

The market is filled with gapping stocks in Monday's session. ↗

November 24, 2025

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

November 24, 2025

Via Chartmill

Frequently Asked Questions

Is ProMIS Neurosciences Inc. - Common Shares publicly traded?

Yes, ProMIS Neurosciences Inc. - Common Shares is publicly traded.

What exchange does ProMIS Neurosciences Inc. - Common Shares trade on?

ProMIS Neurosciences Inc. - Common Shares trades on the Nasdaq Stock Market

What is the ticker symbol for ProMIS Neurosciences Inc. - Common Shares?

The ticker symbol for ProMIS Neurosciences Inc. - Common Shares is PMN on the Nasdaq Stock Market

What is the current price of ProMIS Neurosciences Inc. - Common Shares?

The current price of ProMIS Neurosciences Inc. - Common Shares is 14.66

When was ProMIS Neurosciences Inc. - Common Shares last traded?

The last trade of ProMIS Neurosciences Inc. - Common Shares was at 08/17/26 04:00 PM ET

What is the market capitalization of ProMIS Neurosciences Inc. - Common Shares?

The market capitalization of ProMIS Neurosciences Inc. - Common Shares is 479.22M

How many shares of ProMIS Neurosciences Inc. - Common Shares are outstanding?

ProMIS Neurosciences Inc. - Common Shares has 479M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.